EMA CHMP gives positive recommendation on CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myeloma

  The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA – the EU medicines regulator) has today given a positive recommendation for the extension of the marketing authorisation for the CAR-T treatment ciltacabtagene autoleucel (Carvytki®), also known as cilta-cel, for use in patients who have received at least 1 prior therapy. The full wording of the license extension is as follows:   Carvykti is indicated for the treatment of…

US FDA approves bi-weekly teclistamab dosing in relapsed/refractory myeloma

  The US Food and Drug Administration (FDA – the medicines regulator in the US) has granted approval to a “supplemental biologics license application” for teclistamab-cqvy (Tecvayli®). This means the existing FDA teclistamab license has been extended to include administration at a reduced dosing frequency of 1.5 mg/kg every two weeks, instead of once weekly (as is currently the case) for patients with relapsed/refractory myeloma who have maintained a sustained complete response (CR – a…

AMEN provides medical information for Arabic speakers in Israel and beyond

  The population of Israel today is 9.8 million people. Among them, 20% are Arabs (about 2 million people) whose first language is Arabic. Due to this, the Israel Multiple Myeloma Association, AMEN, decided to promote multiple activities that will support Arabic-speaking patients with information about myeloma.   The activities included: A website in Arabic, similar to the one that is running in Hebrew. Translation of an online system that searches the relevant rights of…

GSK announces results from interim analysis of the DREAMM-7 phase III trial

  On 6 February 2024, GlaxoSmithKline (GSK) announced results from an interim analysis of the DREAMM-7 phase III trial presented at an American Society of Clinical Oncology (ASCO) online plenary session. The trial is evaluating belantamab mafodotin (“belamaf” or trade name Blenrep®) combined with bortezomib plus dexamethasone (BorDex) versus daratumumab plus BorDex in second line and later treatment of relapsed or refractory myeloma.   Key results from the presentation include: A main research question in…

EMA CHMP gives positive opinion on CAR-T treatment idecabtagene vicleucel (Abecma) in earlier lines of therapy for relapsed and refractory myeloma

The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has given a positive recommendation for the extension of the marketing authorisation for idecabtagene vicleucel (ide-cel), a CAR-T treatment marketed by BMS as Abecma®. Ide-cel is currently approved for the treatment of patients with relapsed and refractory myeloma, who have received at least three previous lines of therapy. The extension means that ide-cel will now be indicated for the treatment…

MPE announces partnership in EU consortium project CERTAINTY: advancing cancer care through virtual twins in personalised immunotherapy

  MPE announces partnership with an international team, including representatives from scientific, industry, and healthcare sectors, as part of the EU-funded research project CERTAINTY, which began in December 2023. The EU consortium “CERTAINTY – A cellular immunotherapy virtual twin for personalized cancer treatment” is being funded by the European Union with almost EUR 10 million over the next 4.5 years within the Horizon Health 2023 program. The project, led by the Fraunhofer Institute for Cell Therapy…

ASH 2023 | Myeloma and AL amyloidosis updates

Myeloma Patients Europe (MPE) attended the 65th American Society of Hematology (ASH) Annual Meeting, the largest haematology congress, held from 9 to 12 December in San Diego (United States). MPE has interviewed haematology experts to summarise the latest myeloma and AL amyloidosis updates.     Prof. Dr. Michel Delforge, Department of Haematology, University Hospital Leuven, Belgium, explains the latest findings on the KarMMa-3 trial and the impact abecma has on Quality of Life (QoL) presented at…

Sign up for the MPE webinar on ASH 2023 myeloma and AL amyloidosis highlights

Myeloma Patients Europe (MPE) will host a webinar to summarise the most important myeloma and AL amyloidosis updates presented at the 65th American Society of Hematology (ASH) Annual Meeting which will be held 9-12 December, 2023 in San Diego, California, United States.   The webinar will take place on Wednesday, 17 January from 17:00 to 18:00 CET and will be given by Dr. Faith Davies, Director of Clinical Myeloma Programme at NYU Langone Health Perlmutter…

2023: Year in Review

On behalf of the Myeloma Patients Europe (MPE) Board of Directors and staff, we extend a heartfelt thank you to our members, sponsors and stakeholders for your dedication and inspiration.   This year, MPE achieved significant milestones made possible by our collective efforts, and we are thrilled to present our Year in Review 2023. We hope you’ll take a moment to read this report, which highlights our key accomplishments focused on empowering, educating and supporting the patient…